CD ComputaBio and Insilicom Forge Strategic Alliance to Advance Preclinical Drug Development through Knowledge-Graph AI

NEW YORK, NY — CD ComputaBio has officially signed a strategic partnership agreement with Insilicom, a developer of advanced AI-driven platforms for biomedical knowledge discovery. This alliance is designed to bridge the gap between computational chemistry and preclinical drug development, utilizing data-driven insights to enhance drug efficacy and safety profiles.

Through this partnership, CD ComputaBio will integrate Insilicom’s specialized tools, such as the Biomedical Knowledge Discovery Engine (BioKDE) and the IDEAL tool suite, into its preclinical service workflow. This integration will allow for more robust target identification, drug repurposing, and pharmacovigilance modeling. By applying Insilicom’s deep learning-powered knowledge graphs, CD ComputaBio can offer clients a more holistic view of how potential drug candidates interact with biological systems at a systemic level.

"Partnering with Insilicom allows us to transition from 'designing' a molecule to 'predicting' its behavior in complex biological environments," noted the Head of Drug Development at CD ComputaBio. "This collaboration empowers our clients to make data-backed decisions during the critical preclinical phase, ultimately increasing the success rate of clinical trials."

The collaboration will specifically focus on:

Target Validation: Using structured knowledge graphs to identify and validate novel disease targets.
Safety Prediction: Early-stage identification of potential adverse effects through AI-powered literature monitoring.
Data Harmonization: Streamlining the analysis of multi-omics data to support preclinical candidate selection.

About CD ComputaBio

Headquartered in New York, CD ComputaBio provides professional computational biology analysis to researchers worldwide, supporting everything from basic protein modeling to complex drug optimization.

About Insilicom

Insilicom is a Massachusetts-based AI company specializing in biomedical big data and knowledge discovery. Its platforms enable scientists to extract structured insights from vast amounts of unstructured biological data, accelerating the path from research to therapy.